Piper Jaffray Cuts ViroPharma to Market Perform

Analyst Thomas Wei notes the possibility of sooner-than-expected generic competition for the company's Vancocin drug

Piper Jaffray downgraded ViroPharma (VPHM) to market perform from outperform, after the company said Friday that the Food and Drug Administration may have taken a new stance on bioequivalence testing for the drug Vancocin.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.